Back

Vermont

Vermont has comprehensive shield laws (PDF, opens in a new tab) to help protect reproductive and gender-affirming health care provided to patients regardless of their location, which includes telehealth care.

Vermont should further strengthen its protections for providers, helpers, and patients by focusing on these policy priorities:

01

Prevent Disclosure of Patients' Medical Information

02

Prevent Disclosure of Other Data Related to Reproductive and Gender-Affirming Care

03

Protect Against State Misbranding Actions

01

Prevent Disclosure of Patients' Medical Information

Research shows that criminal cases brought against people for self-managed abortions (PDF, opens in a new tab) and other pregnancy outcomes (PDF, opens in a new tab) are commonly brought to the attention of law enforcement by health care providers. Although federal law under HIPAA offers some privacy protection for patients’ medical information, HIPAA contains exceptions that some providers have interpreted as permitting them to disclose sensitive patient health information to law enforcement. To counter this, Vermont and some other shield states have enacted more comprehensive privacy protections against health care providers and related entities disclosing a patient’s health information where it may be used to investigate or penalize lawful abortion or gender-affirming care.

To further safeguard patient medical information, Vermont should consider joining the several shield states that have also enacted specific protections responding to our interoperable electronic health record system, where medical records may be automatically shared across state lines through health information exchanges (HIEs). HIEs may automatically transfer data from states where abortion and gender-affirming care is lawful to states where it is banned and heavily surveilled. Recognizing this risk, some shield states have enacted laws requiring heightened security within electronic health records for information related to reproductive and gender-affirming care and prohibiting that information from being shared across state lines through HIEs. Vermont should make this policy a priority in 2027.

02

Prevent Disclosure of Other Data Related to Reproductive and Gender-Affirming Care

In addition to protected health information collected by health care providers and other HIPAA covered entities, private businesses may also collect data—including communications, location, and financial transactions—revealing a person’s reproductive or gender-affirming care history. These businesses are generally not subject to HIPAA, and in the absence of other laws governing their disclosures, they may share the data they collect to hostile state law enforcement or private entities seeking to penalize a person for accessing reproductive or gender-affirming care. To help protect personal data, some shield states have enacted legislation preventing businesses incorporated or operating in the state from providing information in response to an out-of-state subpoena or other legal process relating to legally protected health care.

The disclosure of geolocation data also raises surveillance concerns for patients, helpers, and providers of reproductive and gender-affirming care. In 2025, Texas law enforcement (opens in a new tab) searched Flock surveillance data to track a woman traveling out of state for abortion care. Some shield states have begun enacting laws to prohibit geofencing around health care facilities and the disclosure of automatic license plate reader data for the purposes of investigating legally protected health care activity.

Vermont should make these data privacy policies a priority in 2027.

03

Protect Against State Misbranding Actions

Despite decades of scientific evidence conclusively demonstrating the safety and effectiveness of mifepristone and other drugs commonly used for medication abortion, the anti-abortion movement has aggressively targeted (opens in a new tab) these medications, including by demanding FDA revoke approval of mifepristone, which was granted more than 25 years ago. Anti-abortion extremists have also demanded that unnecessary and burdensome restrictions be placed on mifepristone, including requiring it to be dispensed in person. Some shield law states have enacted (opens in a new tab) laws designed to protect against claims of misbranding under state law in the event FDA takes action affecting the approval or regulation of mifepristone or other safe and effective drugs used for medication abortion. Vermont should make this policy a priority in 2027.

Opens your browser's print dialog. Choose Save as PDF.